Absence of Plekhg5 Results in Myelin Infoldings Corresponding to an Impaired Schwann Cell Autophagy, and a Reduced T-Cell Infiltration Into Peripheral Nerves
Inflammation and dysregulation of the immune system are hallmarks of several neurodegenerative diseases. An activated immune response is considered as the cause of myelin breakdown in demyelinating disorders. In the peripheral nervous system, myelin can be degraded in an autophagy-dependent manner d...
Saved in:
Published in | Frontiers in cellular neuroscience Vol. 14; p. 185 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Lausanne
Frontiers Research Foundation
07.07.2020
Frontiers Media S.A |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Inflammation and dysregulation of the immune system are hallmarks of several neurodegenerative diseases. An activated immune response is considered as the cause of myelin breakdown in demyelinating disorders. In the peripheral nervous system, myelin can be degraded in an autophagy-dependent manner directly by Schwann cells or by macrophages, which are modulated by T-lymphocytes. Here, we show that the NF-κB activator Pleckstrin homology containing family member 5 (Plekhg5) regulates both, Schwann cell autophagy and recruitment of T-lymphocytes in peripheral nerves during motoneuron disease. Plekhg5-deficient mice show defective axon/Schwann cell units characterized by myelin infoldings in peripheral nerves. Even at late stages, Plekhg5-deficient mice do not show any signs for demyelination and inflammation. Using RNAseq we unraveled a transcriptional signature for an impaired immune response in sciatic nerves, which manifested in a reduced number of CD4+ and CD8+ T-cells. These findings identify Plekhg5 as a promising target to impede myelin breakdown in demyelinating PNS disorders. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Reviewed by: John Svaren, University of Wisconsin-Madison, United States; Douglas Fields, National Institutes of Health (NIH), United States; Ye Zhou, Regeneron Pharmaceuticals, Inc., United States Specialty section: This article was submitted to Non-Neuronal Cells, a section of the journal Frontiers in Cellular Neuroscience These authors have contributed equally to this work Edited by: Veronica Ines Brito, Vall d’Hebron University Hospital, Spain |
ISSN: | 1662-5102 1662-5102 |
DOI: | 10.3389/fncel.2020.00185 |